People with diffuse large B-cell lymphoma or follicular lymphoma and limited treatment options could benefit from new drug
People with certain mutations (genetic changes) in their lymphoma cells are most likely to benefit.
News
Research and clinical trials
Read the latest news and views from Lymphoma Action.
Use the drop down filter to find the most relevant news for you.
Encouraging initial results for newer drugs to treat diffuse large B-cell lymphoma
MOR2018 and lenalidomide could be a new treatment combination for diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond well) to previous treatment.
CHOP remains standard treatment for T-cell lymphoma
New approaches are needed for the treatment of people with T-cell lymphoma after disappointing results in the CHEMO-T trial.
Rituximab can help children with NHL
Adding rituximab to chemotherapy improves outcomes for under-18s with advanced-stage B-cell non-Hodgkin lymphoma (NHL)
RATHL trial: Reducing serious side effects and improving outcomes
Recently published findings from the phase 3 RATHL trial (Response-adapted therapy for advanced Hodgkin lymphoma) show that most people can be spared some side effects.